Search

Search

这页已由机器翻译。其他页面可能仍然显示为英文。 View in English

首页
...
研究领域生物医学和临床科学瘤学和致癌症预测和预后标志物
患者对临床病理和基因组工具在早期乳腺癌治疗中的看法

患者对临床病理和基因组工具在早期乳腺癌治疗中的看法

Ana-Alicia Beltran-Bless ^1,2, Deanna Saunders ², Lucas Clemons ², Igor Machado ¹, Gregory Pond ³, Brian Hutton ⁴, Khaled El-Emam ^5,6, Sharon McGee ^1,2, Terry L Ng ^1,2, Marie-France Savard ^1,2, John Hilton ^1,2, Moira Rushton ^1,2, Gail Larocque ⁷, Sabine Siesling ^8,9, Andreanne Leblanc ¹, Lisa Vandermeer ², Mark Clemons ^10,11,12

Ana-Alicia Beltran-Bless ^1,2, Deanna Saunders ², Lucas Clemons ²

¹Division of Medical Oncology, Department of Medicine, The University of Ottawa, Ottawa, Canada.
²Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, Canada.
³Department of Oncology, McMaster University, Hamilton, Canada.
⁴Methods and Implementation Research Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
⁵CHEO Research Institute, Ottawa, ON, Canada.
⁶School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
⁷The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
⁸Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, Netherlands.
⁹Department Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
¹⁰Division of Medical Oncology, Department of Medicine, The University of Ottawa, Ottawa, Canada. mclemons@toh.ca.
¹¹Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, Canada. mclemons@toh.ca.
¹²The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. mclemons@toh.ca.

⁰Division of Medical Oncology, Department of Medicine, The University of Ottawa, Ottawa, Canada.

Breast Cancer Research and Treatment +

|

2025年八月21日

相关实验视频

These videos have been matched automatically. Contact us if they are not relevant.

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

See all related videos

在PubMed上查看摘要

概括

此摘要是机器生成的。

许多早期乳腺癌患者不知道使用的预后工具,影响他们对复发风险和治疗益处的理解. 需要更清晰的沟通, 以使患者的看法与实际风险评估保持一致.

科学领域

癌症学
医疗信息学
患者报告的结果

背景情况

预测和预测工具对于早期乳腺癌 (EBC) 的管理至关重要.
这些工具有助于确定患者的预后,并预测治疗效果.
然而,患者对这些工具的理解和感知仍未得到充分探索.

研究的目的

评估患者对EBC护理中的预后/预测工具的认识和认知.
评估这些工具如何影响患者对个人复发风险和治疗益处的理解.
从预测工具和可接受的治疗效益值中确定患者的优先权.

主要方法

对EBC患者进行了一项关于预后/预测工具的调查.
患者自我报告的复发风险与INFLUENCE 2.0工具估计的实际风险进行了比较.
收集了关于化疗所需的工具输出和感知到的益处的数据.

主要成果

只有26%的受访患者知道进行了预后测试,尽管50%的人使用了NHS PREDICT 2.1.
患者自我评估的风险与实际风险存在轻微关联 (INFLUENCE 2.0).
患者优先考虑转移和无疾病存活率的信息;化学疗法接受值较低,特别是在以前接受过治疗的人群中.

结论

在EBC中广泛使用预后/预测工具并不能保证患者的意识.
缺乏意识可能导致感知和实际疾病复发风险之间的差异.
需要改进沟通策略,以提高患者对预后信息的理解和参与度.

关键词:

乳腺癌预测性预测情况风险评估

相关实验视频

这些视频已自动匹配 Contact us 如果它们不相关

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

See all related videos

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies